Clinical Trials Sponsored by Suzhou Genhouse Bio Co., Ltd.

Total 841 results

MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer (mCRPC)

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

KRAS G12C Mutant Advanced Solid Tumors

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Solid Tumor | KRAS Mutation-Related Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Advanced Colorectal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

Healthy Participants | Atopic Dermatitis Patients

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
GeneQuantum Healthcare (Suzhou) Co., Ltd.

Recruiting

A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

HER2 Expressing or Mutated Advanced Malignant Solid Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

China
Suzhou BlueHorse Therapeutics Co., Ltd.

Recruiting

A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

MSI-H

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Study of ZG0895.HCl in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

Ankylosing Spondylitis

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Suzhou Transcenta Therapeutics Co., Ltd.

Recruiting

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Colorectal Adenocarcinoma | Locally Advanced Solid Tumor | Metastatic Tumor

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)

Novel COVID-19-Infected Pneumonia

China
EpimAb Biotherapeutics (Suzhou)Co., Ltd.

Recruiting

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Advanced/Metastatic Solid Tumors | Relapse/Refractory Lymphoma

China, Australia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

Atopic Dermatitis

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Relapsed or Advanced Non-small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States, China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients

Active Moderate to Severe Graves' Orbitopathy
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis (UC)

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Diffuse Large B-Cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Korea, Republic of, China, Japan
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

DLBCL

China
Suzhou Junjing BioSciences Co., Ltd.

Recruiting

AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

Lung Cancer

China
Coherent Biopharma (Suzhou) Co., Ltd.

Recruiting

A Study of CBP-1018 in Patients With Advanced Solid Tumors

Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

Hematologic Malignancy

China
Coherent Biopharma (Suzhou) Co., Ltd.

Recruiting

A Study of CBP-1008 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Intense Monitoring Study on Tyvyt

Relapsed or Refractory Classical Hodgkin's Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Indolent Non-hodgkin Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

Cholangiocarcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI362 in Participants With Obesity or Overweight

Obesity Or Overweight

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

ALK-positive Non-small Cell Lung Cancer

China
Suzhou Abogen Biosciences Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine

COVID-19

Philippines, Pakistan, United Arab Emirates, Indonesia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Terminated

A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal

Differentiated Thyroid Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

Gout Arthritis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata (AA)

Alopecia Areata(AA)

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI311 in Subjects With Active Thyroid Eye Disease

Thyroid Eye Disease

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers

Healthy Volunteers

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

ADME Study of [14C]-Jaktinib in Healthy Male Subjects

Healthy Adult Male Volunteers

China

3

Subscribe